XORTX Announces Results of Annual and Special Meeting of Shareholders
13 sept. 2024 07h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A
12 sept. 2024 17h30 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders
06 sept. 2024 17h30 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 06, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
03 sept. 2024 12h30 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism
29 août 2024 07h00 HE
|
XORTX Therapeutics Inc.
● Xanthine oxidase reported to modulate progression of chronic kidney disease, diabetic kidney disease, polycystic kidney disease, and other indications ● CALGARY, Alberta, Aug. 29, 2024 ...
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
23 août 2024 07h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Aug. 23, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024
20 août 2024 07h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Aug. 20, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late-stage clinical pharmaceutical company...
XORTX to Present at BIO International Convention 2024
04 juin 2024 08h30 HE
|
XORTX Therapeutics Inc.
CALGARY, June 04, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on...
XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO
17 mai 2024 07h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX Reprices Warrants Issued in Connection with Previous Private Placements
30 avr. 2024 13h54 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, April 30, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...